HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $3 price target.
August 15, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on TransCode Therapeutics and maintained a $3 price target.
The reiteration of a Buy rating and the maintenance of a $3 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100